Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Unhatched chickens

"Biobucks" have become a standing joke in the industry. But despite warnings about the dubious meaning of dollar signs attributed to deals, industry scorekeepers still look for transactions with gaudy numbers. Nevertheless, the advice still stands: investors and companies would do well to remember not to count their chickens until they are hatched.

A case in point is last week's termination of a May 1996 partnership between CoCensys Inc. and G.D. Searle & Co. to

Read the full 742 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE